



HAL
open science

The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways

Solange Tréhoux, Bélinda Duchêne, Nicolas Jonckheere, Isabelle van Seuningen

► To cite this version:

Solange Tréhoux, Bélinda Duchêne, Nicolas Jonckheere, Isabelle van Seuningen. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. *Biochemical and Biophysical Research Communications*, 2014, 10.1016/j.bbrc.2014.12.025 . hal-02905690

HAL Id: hal-02905690


<https://hal.science/hal-02905690>

Submitted on 29 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

AUTHOR QUERY FORM

	Journal: YBBRC Article Number: 33131	Please e-mail or fax your responses and any corrections to: E-mail: corrections.esch@elsevier.sps.co.in Fax: +31 2048 52799
---	---	---

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
<p><u>Q1</u></p>	<p>Please confirm that given name(s) and surname(s) have been identified correctly.</p> <div data-bbox="416 1868 979 1970" style="border: 1px solid black; padding: 5px; margin-top: 20px;"> <p style="color: red;">Please check this box if you have no corrections to make to the PDF file</p> <input data-bbox="868 1885 940 1949" type="checkbox"/> </div>

Thank you for your assistance.

Highlights

• Loss of MUC1 decreases proliferation and tumor growth via β -catenin and p42–44 MAPK. • Inhibition of MUC1 decreases cell migration and invasion through MMP13. • Loss of MUC1 decreases survival and increases apoptosis via Akt and Bcl-2 pathways. • Loss of MUC1 sensitizes cells to gemcitabine and 5-Fluorouracil chemotherapeutic drugs.



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42–44 MAPK, Akt, Bcl-2 and MMP13 pathways

Solange Tréhoux, B elinda Duch ene, Nicolas Jonckheere, Isabelle Van Seuningens*

Inserm, UMR837, Jean-Pierre Aubert Research Center, Team 5 "Mucins, Epithelial Differentiation and Carcinogenesis", Rue Polonovski, 59045 Lille Cedex, France
Universit e de Lille 2, 42 rue Paul Duez, 59000 Lille, France
Centre Hospitalier R egional et Universitaire de Lille, 59037 Lille Cedex, France

ARTICLE INFO

Article history:
Received 3 December 2014
Available online xxxx

Keywords:
Pancreatic cancer
MUC1
Proliferation
Migration
Invasion
Chemoresistance

ABSTRACT

MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To this aim, we undertook to study MUC1 biological effects on pancreatic cancer cells and identify pathways mediating these effects. Our *in vitro* experiments indicate that inhibiting MUC1 expression decreases cell proliferation, cell migration and invasion, cell survival and increases cell apoptosis. Moreover, lack of MUC1 in these cells profoundly altered their sensitivity to gemcitabine and 5-Fluorouracil chemotherapeutic drugs. *In vivo* MUC1-KD cell xenografts in SCID mice grew slower. Altogether, we show that MUC1 oncogenic mucin alters proliferation, migration, and invasion properties of pancreatic cancer cells and that these effects are mediated by p42–44 MAPK, Akt, Bcl-2 and MMP13 pathways.

  2014 Published by Elsevier Inc.

1. Introduction

The mucins are a family of large O-glycoproteins divided into two groups: secreted mucins and membrane-bound mucins [1]. Secreted mucins are involved in the protection of epithelial cells to external influences such as inflammation, pathogens or pH variations by forming the mucus gel which is a physical protective barrier of epithelia. Membrane-bound mucins are involved in cell interactions and cell signaling by transmitting intracellular signals of cell survival and cell growth under stress condition. The mucin MUC1 is a membrane-bound mucin expressed at the apical pole of normal epithelial polarized cells [2,3]. In cancer cells, MUC1 is frequently overexpressed, internalized, circumferentially delocalized around the tumor cell surface when cells lose polarity. MUC1 becomes oncogenic as it is involved in several oncogenic pathways leading to altered cell properties such as cell growth, cell migration and invasion [4]. These profound modifications result from the interaction of MUC1 with tyrosine kinase receptors such

as EGFR and the activation of oncogenic signaling pathways like MAPK, Akt or Wnt/ β -catenin [5–7].

Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth leading cause of death by cancer in Western countries and has a very poor prognosis due to a late diagnosis and a lack of efficient treatment. PDAC have a dramatic outcome with the 5 years survival rate lower than 5% [8]. Less than 20% of patients are entitled to surgical resection and the remaining 80% of patients present a locally advanced metastatic PDAC [9]. They may benefit from palliative chemotherapy based either on gemcitabine or FOLFIRINOX composed of 5-Fluorouracil (5-Fu), oxaliplatin and SN-38 [10]. In 90% of PDAC, the mucin MUC1 is overexpressed and MUC1 was proposed as one of the most robust predictive marker of PDAC survival [11,12]. It was shown that MUC1 induced EMT [13] and resistance to gemcitabine [14] and also increased cell invasion through Stat3 [15] and PDGR- β [16]. For these reasons MUC1 appears as an attractive target to moderate pancreatic cancer progression.

To better understand MUC1 biological effects on PDAC cells, we undertook to study its effects both *in vitro* and *in vivo* and the underlying cellular mechanisms mediating these effects. We generated stable cell lines knocked-down for MUC1 and showed *in vitro* that inhibiting MUC1 decreased cell proliferation via p42–44 MAPK, cell migration and invasion via MMP13, cell survival and apoptosis via Akt and Bcl2, and tumor growth *in vivo*. These

* Corresponding author at: Inserm, UMR837, Jean-Pierre Aubert Research Center, Team 5 "Mucins, Epithelial Differentiation and Carcinogenesis", Rue Polonovski, 59045 Lille Cedex, France. Fax: +33 320 53 85 62.

E-mail address: isabelle.vanseuningens@inserm.fr (I. Van Seuningens).

2

S. Tréhoux et al. / Biochemical and Biophysical Research Communications xxx (2014) xxx–xxx

82 results confirmed the potential of MUC1 as an attractive target to
83 slow-down PDAC progression.

84 2. Materials and methods

85 2.1. Cell culture and establishment of MUC1-KD stable cell lines

86 Capan-2 cell line was purchased from ATCC and was cultured as
87 described previously [17]. Capan-2 stable cell lines knocked-down
88 (KD) for MUC1 (Capan-2 MUC1-KD1/2) were generated by retro-
89 viral infection as previously described [18] using MUC1-Sh1 pri-
90 mers FP: GATCCCCACCTCCAGTTTAATTCCTCTCAAGAGAGAGGAAT
91 TAAACTGGAGGTTTTTTA and RP: GGGTGGAGGTGCAATTAAGGAGA
92 AGTTCTCTCTCTTAATTCGACCTCAAAAAATTCTGA. MUC1-Sh2 pri-
93 mers FP: GATCCCATGTTTTGCAGATTATATCAAGAGATATAAAT
94 CTGCAAAAACATTTTTTA and RP: GGGTACAAAAACGT CTAATATA
95 AGTTCTCTATATTAGACGTTTTGTAAAAAATTCTGA.

96 2.2. Cell proliferation, migration and invasion assays

97 Stable cell lines were seeded at 10^5 cells per well in 6-well
98 plates. Cells were counted daily using a Malassez counting cham-
99 ber using Trypan Blue exclusion dye (Life Technologies) during
100 96 h. Invasion and migration assays were respectively performed
101 using 24-well Boyden chambers (8 μ m pores) coated or not with
102 Matrigel™ (Pharmingen, BD Biosciences). Briefly, 5×10^4 cells
103 were seeded on the top chamber and FBS 10% (v/v) was used as
104 a chemoattractant in the bottom chamber for 24 h. Staining were
105 performed using Vectashield hard set mounting medium with
106 DAPI H-1500 (4',6'-diamidino-2-phénylindole) (Vector labs). Three
107 independent experiments were performed in triplicate.

108 2.3. Cytotoxicity assay

109 10^4 cells were seeded in 96-well plates during 24 h. Medium
110 was refreshed with gemcitabine, 5-Fu, oxaliplatin or SN-38
111 for 72 h. The viability of cells was determined using 3-(4,
112 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay
113 (MTT, Sigma–Aldrich, Saint Quentin Fallavier, France) as previously
114 described [17]. Formazan crystals were solubilized in dimethyl-
115 sulfoxide (Sigma–Aldrich) and analyzed at 570 nm with a micro-
116 plate reader (Bio-Rad).

117 2.4. Quantitative reverse transcription-polymerase chain reaction 118 (qRT-PCR)

119 Total RNA was extracted using miRNeasy Mini Kit with Qiazol®
120 (Qiagen) according to the manufacturer's instructions. cDNA was
121 prepared as previously described. qPCR was performed using Sso-
122 Fast Evagreen® Supermix (Bio-Rad) and the CFX96 real time PCR
123 system (Bio-Rad). Expression levels of MUC1 (FP: TGCCGCCGAAAG
124 AACTACG and RP: TGGGGTACTCGCTCATAGGAT) were normalized
125 to GAPDH (FP: CCACATCGCTCAGACACCAT and RP: CCAGGCGCCC
126 AATACG). Expression levels were calculated using the $2^{-\Delta\Delta Ct}$
127 method. Three independent experiments were performed.

128 2.5. Protein extraction and Western-blot analysis

129 Total proteins were extracted, electro-transferred, immunos-
130 tained, and visualized as described before [19]. Antibodies used
131 were MUC1 (M8, 1/250, from Pr. D. Swallow); β -actin (A5441
132 AC15, 1/5000) from Sigma–Aldrich; cyclin D1 (sc-718, 1/250),
133 CDK6 (sc-177, 1/250) from Santa Cruz; Bcl-2 (#2872, 1/250), phos-
134 pho p42–44 MAPK (#9101, 1/500), p42–44 MAPK (#9102, 1/500),

β -catenin (#8480s, 1/1000), phospho AKT (#4060, 1/500), AKT
135 (#4691s, 1/500) from Cell Signaling, Ozyme; MMP13 (Ab39012,
136 1/1000) from Abcam. Bands were quantified with image J analysis
137 software three independent experiments were performed. 138

2.6. Subcutaneous xenografts

139 Subcutaneous (SC) xenografts (2×10^6 cells in 100 μ l of RPMI
140 1640) of MUC1-Mock, MUC1-KD1 and MUC1-KD2 cell lines were
141 carried out with 100 μ l of Matrigel™ (BD Biosciences) into the
142 flank of severe-combined immunodeficient (SCID) male mice
143 (CB-17, Charles Rivers) that were bred and maintained under
144 pathogen-free conditions (6 mice/group). Tumor development
145 was followed weekly. The tumor volume (mm^3) was determined
146 by calculating $V = W \times L$ in which W corresponds to the width
147 (mm) and L to the tumor length (mm). Mice were sacrificed
148 28 days after inoculation. All procedures were performed in accor-
149 dance with the guidelines and approved by the animal care ethical
150 committee (Comité Ethique Expérimentation Animale Nord Pas-
151 de-Calais, CEEA #122012). 152

2.7. Immunohistochemistry

153 Tumor xenografts were fixed in 10% (w/v) buffered formalde-
154 hyde, paraffin-embedded, cut at 4 μ m thickness and applied on
155 SuperFrost® slides (Menzel-Glaser, Thermo Scientific). Histology
156 was assessed by staining tissues with Hematoxylin-Eosin. Auto-
157 matic IHC was performed with an automated immunostainer (ES,
158 Ventana Medical System, Strasbourg, France) as described [20].
159 Immunostainings in xenografts were carried out with anti-MUC1
160 M8 Mab (1/50) antibodies. 161

2.8. Gene Expression Omnibus microarray

162 Public PC microarrays were analyzed from the NCBI Gene
163 Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>). A set of gene-expression profiles from GEO containing
164 both normal pancreas and PC tissue were used: 45 tumors and
165 adjacent non-tumor tissues from PDAC cases (GSE28735). Data
166 were analyzed using GEO2R software. The dataset GSE28735 used
167 Affymetrix GeneChip Human Gene 1.0 ST array. 168

2.9. Statistical analyses

169 Statistical analyses were performed using Graphpad Prism 4.0
170 software (Graphpad softwares Inc.). Data are presented as
171 mean \pm SD or \pm SEM. Differences in the mean of samples were ana-
172 lyzed by the student's t test or one way ANOVA test with selected
173 comparison using Tukey's HSD post-hoc test. Differences less than
174 0.05 considered significant and were indicated with a *, ** indicates
175 $p < 0.01$, *** indicates $p < 0.001$. 176

3. Results

3.1. Silencing of MUC1 in Capan-2 PDAC cell line

177 In order to study the functional role of MUC1 in PDAC we gen-
178 erated two stable cell lines knocked-down for MUC1 by short-
179 hairpin RNA (Sh-RNA) approach. The MUC1 decreased expression
180 in MUC1-KD cells compared to control Mock cells was confirmed
181 by qRT-PCR (Fig. 1A) ($p < 0.05$) and by Western-blot (Fig. 1B). 182
183
184

3.2. Inhibiting MUC1 decreased PDAC cell growth in vitro

Cells knocked-down for MUC1 showed a statistically significant decrease of cell proliferation (Fig. 1C), at 72 and 96 h ($p < 0.001$). To identify the mechanisms underlying the alterations of cell proliferation mediated by MUC1 knock-down, we measured the activation of the major signaling markers/pathways in the three cell lines. Accordingly to the decreased cell proliferation, we observed a decrease of phospho p42-44 MAPK, cyclin D1 and β -catenin that was more pronounced in the MUC1-KD2 cell line than in the MUC1-KD1 (Fig. 1D).

3.3. Inhibiting MUC1 decreased PDAC cell migration and invasion in vitro

Next to cell proliferation, we decided to evaluate MUC1 properties on migration and invasion capacity of PDAC cells. Using Boyden chambers and DAPI staining we showed a statistically significant decrease of cell migration in MUC1-KD2 cells ($p < 0.01$) (Fig. 2A). Invasive capacities of MUC1-KD cells were statistically decreased both in MUC1-KD1 ($p < 0.05$) and in MUC1-KD2 ($p < 0.01$) cells when compared to Mock cells (Fig. 2A). In order to identify the molecular mechanisms involved in the alteration of cell migration and invasion through MUC1 inhibition, we measured the expression level of metalloprotease MMP13. Accordingly to the inhibition of cell migration and invasion, we observed a decrease of MMP13 expression both in MUC1-KD1 and MUC1-KD2 cells compared to Mock cells (Fig. 2B).

3.4. Inhibiting MUC1 decreased PDAC cell survival, increased apoptosis and gemcitabine and 5-Fu sensitivity in vitro

Investigation of the implication of MUC1 in survival and apoptosis pathways using Western-blotting, indicated a decrease of phospho-Akt expression and a decrease of anti-apoptotic marker Bcl-2 in MUC1-KD cells compared to Mock cells (Fig. 2C). PDAC being an extremely chemoresistant cancer, we undertook to evaluate MUC1 effect on PDAC cell chemosensitivity to gemcitabine or FOLFIRINOX drugs (5-Fu, oxaliplatin and SN-38). Measurement of cell survival following drug treatment indicated that inhibition of MUC1 led to a mild (MUC1-KD1) and a strong (MUC1-KD2) decrease of cell viability following treatment with gemcitabine or 5-Fu ($p < 0.5$ and $p < 0.01$) (Fig. 2D). We did not observe variation on sensitivity after treatment with oxaliplatin or SN-38. Altogether, these results indicate that PDAC cells down-expressing MUC1 harbor altered cell survival and apoptosis in vitro and are more sensitive to gemcitabine and 5-Fu chemotherapeutic drugs.

3.5. In vivo biological properties of PDAC cells stably knocked-down for MUC1

Having shown in vitro that MUC1 plays a role in Capan-2 cell growth, we undertook to evaluate their activity in vivo. To this aim, subcutaneous (SC) xenografts of Capan-2 MUC1-KD cells were performed in SCID mice. A significant decrease of tumor growth




Fig. 1. Establishment of Capan-2 MUC1-KD cells. (A) Analysis of MUC1 mRNA expression in Capan-2 MUC1-KD1 and MUC1-KD2 cell lines by qRT-PCR. MUC1 expression was normalized to control GAPDH. MUC1 expression in Mock cells was arbitrarily set to 1 ($p < 0.05^*$). (B) Analysis of MUC1 protein expression by Western-blot. (C) Measurement of cell proliferation for 96 h by cell counting and trypan blue exclusion dye ($p < 0.01^{**}$). (D) Analysis of MUC1, β -catenin, cyclin D1, phospho-p42-44 MAPK, p42-44 MAPK, and CDK6 expression by Western-blot. β -Actin was used as internal control.

($p < 0.01$) was found 28 days post xenografts when compared to control Mock cells (Fig. 3A). Tumor weights were also significantly decreased for MUC1-KD1 ($p < 0.05$) and for MUC1-KD2 ($p < 0.01$) (Fig. 3B). We confirmed by IHC the down-expression of MUC1 in SC xenografts (Fig. 3C). Altogether these results indicate that inhibiting MUC1 *in vivo* slow-down pancreatic tumor growth.

3.6. Expression of MUC1 and MMP13 in human PDAC samples

To correlate our MUC1/MMP13 data obtained in PDAC cell lines with human PDAC samples we used PDAC datasets of the NCBI Gene Expression Omnibus (GEO, GSE28735) database. MUC1 and MMP13 mRNA expression was measured in 45 tumors (PDAC) and adjacent non tumor tissues (Control). We observed that MUC1 and MMP13 expression was significantly increased in PDAC tumors ($p < 0.001$) compared to control samples (Fig. 3D)

indicating a correlation between MUC1 and MMP13 overexpression in human PDAC.

4. Discussion

The oncomucin MUC1 is overexpressed in several epithelial cancers [12] including PDAC in which MUC1 overexpression is associated with a short survival rate [11]. In this report we have shown that stable inhibition of MUC1 in Capan-2 human pancreatic cancer cells decreased both their *in vitro* and *in vivo* behavior including cell proliferation, migration and invasion, increased apoptosis and gemcitabine sensitivity, and decreased tumor growth.

Our results suggest that the inhibition of cell migration and invasion may be mediated through the down-expression of MMP13 (collagenase 3) observed in PDAC cells. It was previously




Fig. 2. *In vitro* biological properties of Capan-2 MUC1-KD cells. (A) Results are expressed as a percentage of migration or invasion of cells compared to the control Mock cells (100%). The DAPI staining is shown ($p < 0.05^*$ or $p < 0.01^{**}$). (B) Analysis of MMP13 protein expression by Western-blot. (C) Analysis of P-Akt, Akt and Bcl-2 protein expression by Western-blot. (D) Measurement of cell survival after 72 h of treatment of Capan-2 MUC1-KD cells with 40 nM of gemcitabine or 1 μM of 5-Fu, 1 μM of oxaliplatin and 3 nM of SN-38 ($p < 0.05^*$ or $p < 0.01^{**}$).

shown that the inhibition of MUC1 in esophageal carcinoma decreased MMP13 expression and cell proliferation and migration [18]. MUC1 is composed of two subunits MUC1-N and MUC1-C. MUC1-C is able in a tumorigenic context to be internalized and translocated to the nucleus and act as a co-factor of gene expression. Moreover, it was demonstrated that the MUC1-C subunit is able to bind with Runx-2 to the promoter of MMP13 and increases its expression in esophageal cancer [21]. In human PDAC samples, we observed a similar expression profile of both *MUC1* and *MMP13* as observed in esophageal carcinoma suggesting that in PDAC MUC1 could also be an activator of MMP13 expression. Indeed, like MUC1, MMP13 overexpression was linked to increased metastasis capacity of several cancers. We thus propose that the simultaneous overexpression of both MUC1 and MMP13 would increase PDAC aggressiveness.

The results of our study also suggest that inhibiting MUC1 decreases both *in vitro* cell proliferation and *in vivo* tumor growth. Additionally, we observed a decrease of cell proliferation markers such as cyclin D1, β -catenin and p42-44 MAPK. It was previously identified that MUC1 is able to co-activate the expression of cyclin D1 through its interaction with β -catenin on the promoter of *cyclin D1* gene thus favoring cell proliferation [22]. Moreover, MUC1 is

able to activate the p42-44 MAPK pathway through its interaction with tyrosine kinase receptor [5]. Thus inhibiting MUC1 leads to decreased cell proliferation through the Wnt/ β -catenin and the p42-44 MAPK pathways.

The mucin MUC1 is able to activate the PI3K/Akt survival pathway [7]. Thus the activation of this pathway may result from an increase of cell chemoresistance through the up-regulation of MDR-related Protein (MRP) detoxifying channels by the co-binding of MUC1 on the *MRP1* promoter with an unknown factor [14]. Thus the inhibition of MUC1 and the decrease of both Akt and gemcitabine resistance in MUC1-KD cells confirms this hypothesis. We also observed an increase of cell sensitivity to 5-Fu in MUC1-KD cells. It was previously shown that inhibition of mucin O-glycosylation by benzyl-alpha-GalNAc is important for 5-Fu sensitization [23,24]. However, for the first time we show a direct implication of MUC1 protein in cancer cell sensitivity to 5-Fu. Additionally, our results showed that the down-expression of MUC1 is able to increase cell apoptosis through the inhibition of anti-apoptotic Bcl-2 protein. Interestingly, it was previously shown that MUC1 is able to interact with Bax to block its pro-apoptotic function [25] or to increase Bcl-x_L anti-apoptosis protein level to increase cell survival and apoptosis [7]. Thus, we propose that MUC1




Fig. 3. *In vivo* effects of MUC1 on PDAC tumor properties. (A) SC xenografts of Capan-2 cells stably knocked-down for MUC1 in SCID mice. Tumor growth (mm³) was evaluated during 28 days ($p < 0.05^*$ and $p < 0.01^{**}$). (B) Tumor weight (g) was measured at the sacrifice ($p < 0.05^*$ and $p < 0.01^{**}$). (C) Analysis of MUC1 expression in SC tumors was carried out by IHC. Magnification $\times 20$. (D) *MUC1* and *MMP13* mRNA expression was evaluated in PDAC datasets of the NCBI Gene Expression Omnibus (GEO, GSE28735) database ($p < 0.001^{***}$).

deficiency in Capan-2 pancreatic cancer cells leads to decreased cell survival, increased cell apoptosis and gemcitabine and 5-Fu sensitivity through Akt and Bcl-2 pathways.

In conclusion, our results show that inhibiting MUC1 in human pancreatic cancer cells profoundly alters their behavior: (i) decreased cell proliferation and tumor growth through the Wnt/ β -catenin and the p42–44 MAPK pathways; (ii) decreased cell migration and invasion through MMP13; (iii) decreased cell survival and increased apoptosis and gemcitabine and 5-Fu sensitivity through the Akt and Bcl-2 pathways. Altogether, these results confirm the interest in inhibiting MUC1 expression in pancreatic cancer and to use MUC1 as a therapeutic target to slow-down PDAC progression.

Grant support

Solange Tréhoux is a recipient of a PhD fellowship of the University of Lille 2. Isabelle Van Seuningen is the recipient of a “Contrat Hospitalier de Recherche Translationnelle” (AVIESAN/CHRT 2010). This work was supported by grants from la Ligue Nationale Contre le Cancer (Equipe Labellisée Ligue 2011–2013, IVS), from SIRIC ONCOLille, Grant INCa-DGOS-Inserm 6041 (IVS) and from “Contrat de Plan Etat Région” CPER Cancer 2007–2013 (IVS).

Conflicts of interest

Authors declare no conflict of interest.

Acknowledgments

We thank D. Swallow (MRC, London, UK) for providing MUC1 M8 antibody. We are grateful to M.H. Gevaert and R. Siminsky (Department of Histology, Faculty of Medicine, University of Lille 2) for their technical help. We thank the IFR114/IMPRT (University of Lille 2) animal facility (D. Taillieu).

References

- [1] N. Jonckheere, I. Van Seuningen, The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies, *Crit. Rev. Oncog.* 14 (2008) 177–196.
- [2] M.A. Hollingsworth, B.J. Swanson, Mucins in cancer: protection and control of the cell surface, *Nat. Rev. Cancer* 4 (2004) 45–60, <http://dx.doi.org/10.1038/nrc1251>.
- [3] D.W. Kufe, Mucins in cancer: function, prognosis and therapy, *Nat. Rev. Cancer* 9 (2009) 874–885, <http://dx.doi.org/10.1038/nrc2761>.
- [4] N. Jonckheere, I. Van Seuningen, The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers, *Biochimie* 92 (2010) 1–11, <http://dx.doi.org/10.1016/j.biochi.2009.09.018>.
- [5] J.A. Schroeder, M.C. Thompson, M.M. Gardner, S.J. Gendler, Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland, *J. Biol. Chem.* 276 (2001) 13057–13064, <http://dx.doi.org/10.1074/jbc.M011248200>.
- [6] J.A. Schroeder, M.C. Adriance, M.C. Thompson, T.D. Camenisch, S.J. Gendler, MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion, *Oncogene* 22 (2003) 1324–1332, <http://dx.doi.org/10.1038/sj.onc.1206291>.

- [7] D. Raina, S. Kharbanda, D. Kufe, The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts, *J. Biol. Chem.* 279 (2004) 20607–20612, <http://dx.doi.org/10.1074/jbc.M310538200>.
- [8] R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, *CA Cancer J. Clin.* 63 (2013) 11–30, <http://dx.doi.org/10.3322/caac.21166>.
- [9] A. Vincent, J. Herman, R. Schulick, R.H. Hruban, M. Goggins, Pancreatic cancer, *Lancet* 378 (2011) 607–620, [http://dx.doi.org/10.1016/S0140-6736\(10\)62307-0](http://dx.doi.org/10.1016/S0140-6736(10)62307-0).
- [10] T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, *N. Engl. J. Med.* 364 (2011) 1817–1825, <http://dx.doi.org/10.1056/NEJMoa1011923>.
- [11] J.M. Winter, L.H. Tang, D.S. Klimstra, M.F. Brennan, J.R. Brody, F.G. Rocha, et al., A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers, *PLoS One* 7 (2012) e40157, <http://dx.doi.org/10.1371/journal.pone.0040157>.
- [12] R.E. Beatson, J. Taylor-Papadimitriou, J.M. Burchell, MUC1 immunotherapy, *Immunotherapy* 2 (2010) 305–327, <http://dx.doi.org/10.2217/imt.10.17>.
- [13] L.D. Roy, M. Sahraei, D.B. Subramani, D. Besmer, S. Nath, T.L. Tinder, et al., MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition, *Oncogene* 30 (2011) 1449–1459, <http://dx.doi.org/10.1038/onc.2010.526>.
- [14] S. Nath, K. Daneshvar, L.D. Roy, P. Grover, A. Kidiyoor, L. Mosley, et al., MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes, *Oncogenesis* 2 (2013) e51, <http://dx.doi.org/10.1038/oncsis.2013.16>.
- [15] J. Gao, M.J. McConnell, B. Yu, J. Li, J.M. Balko, E.P. Black, et al., MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion, *Int. J. Oncol.* 35 (2009) 337–345.
- [16] P.K. Singh, Y. Wen, B.J. Swanson, K. Shanmugam, A. Kazlauskas, R.L. Cerny, et al., Platelet-derived growth factor receptor β -mediated phosphorylation of muc1 enhances invasiveness in pancreatic adenocarcinoma cells, *Cancer Res.* 67 (2007) 5201–5210, <http://dx.doi.org/10.1158/0008-5472.CAN-06-4647>.
- [17] N. Skrypek, B. Duchêne, M. Hebbbar, E. Leteurtre, I. van Seuningen, N. Jonckheere, The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family, *Oncogene* 32 (2013) 1714–1723, <http://dx.doi.org/10.1038/onc.2012.179>.
- [18] C. Gronnier, E. Bruyère, F. Lahdaoui, N. Jonckheere, M. Perrais, E. Leteurtre, et al., The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells, *Biochim. Biophys. Acta* (2014), <http://dx.doi.org/10.1016/j.bbamcr.2014.06.021>.
- [19] N. Jonckheere, N. Skrypek, J. Merlin, A.F. Dessein, P. Dumont, E. Leteurtre, et al., The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways, *PLoS One* 7 (2012) e32232, <http://dx.doi.org/10.1371/journal.pone.0032232>.
- [20] C. Mariette, M. Perrais, E. Leteurtre, N. Jonckheere, B. Hémon, P. Pigny, et al., Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway, *Biochem. J.* 377 (2004) 701–708, <http://dx.doi.org/10.1042/BJ20031132>.
- [21] Q. Ye, Z. Yan, X. Liao, Y. Li, J. Yang, J. Sun, et al., MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13, *Lab. Invest.* 91 (2011) 778–787, <http://dx.doi.org/10.1038/labinvest.2011.12>.
- [22] H. Rajabi, R. Ahmad, C. Jin, M. Kosugi, M. Alam, M.D. Joshi, et al., MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells, *J. Biol. Chem.* 287 (2012) 10703–10713, <http://dx.doi.org/10.1074/jbc.M111.323311>.
- [23] A.V. Kalra, R.B. Campbell, Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours, *Eur. J. Cancer* 45 (2009) 164–173, <http://dx.doi.org/10.1016/j.ejca.2008.10.008>.
- [24] A.V. Kalra, R.B. Campbell, Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain, *Br. J. Cancer* 97 (2007) 910–918, <http://dx.doi.org/10.1038/sj.bjc.6603972>.
- [25] R. Ahmad, M. Alam, H. Rajabi, D. Kufe, The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function, *J. Biol. Chem.* 287 (2012) 20866–20875, <http://dx.doi.org/10.1074/jbc.M112.357293>.